CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Develop

  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us
  • More
    • Home
    • About Us
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisors
      • Partnerships
    • Our Technology
    • People
      • Our Team
      • Career
    • Patients
      • Clinical Trials
    • Media
      • Press Releases
      • In the news
      • Publications
    • Contact Us
  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us

Welcome

Deep eutectic ionic liquids for therapeutics

Deep eutectic ionic liquids for therapeuticsDeep eutectic ionic liquids for therapeuticsDeep eutectic ionic liquids for therapeutics

Transforming ionic liquids into healthcare solutions

Who We Are

Our Advantage

Our Mission

CAGE Bio Inc., currently a resident company at Johnson & Johnson Innovation, JLABS @ MBC BioLabs, is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology.

Our Mission

Our Advantage

Our Mission

We believe that systemic exposure to drugs should be an exception. Our mission is to develop highly

effective products for localized treatment thereby minimizing side effects from systemic exposure.

Our Advantage

Our Advantage

Our Advantage

Deep eutectic ionic liquids exhibit broad-spectrum antimicrobial action in addition to exceptional solvation and permeation enhancement. Deep eutectic ionic liquids have shown the ability to deliver proteins (eg insulin) and charged macromolecules (eg siRNA) across the stratum corneum.

LEADERSHIP

Nitin Joshi, CEO

Carmine J. Durham, CSO

Carmine J. Durham, CSO

20+ years in drug development through approvals in the US and EU. Held senior positions at Elan, Alkermes, ALZA (J&J). Co-Founder, Incline Therapeutics acquired by The Medicines Company.

Carmine J. Durham, CSO

Carmine J. Durham, CSO

Carmine J. Durham, CSO

  30+ years experience in pharma and med tech operations. Held senior positions at Knoll/BASF Pharma, Abbott Laboratories, and BoneCare Int’l. (acquired by Genzyme). Co-Founder and former CEO of Zurex Pharma.

Srini Sripada, CCO

Carmine J. Durham, CSO

Srini Sripada, CCO

  20+ years’ experience building iconic brands including Campbell Soup, Advil analgesics, & Vaseline skin care at blue-chip marketing organizations (P&G, Unilever, Campbell Soup, Pfizer).   


Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.


This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Development and Commercialization of TAGX-0003 for the Treatment of Immunodermatology Diseases Mediated by the IFN-Gamma Pathway

Learn more